Sakata Y, Saito G, Sakata S, Yamaguchi T, et al. Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS). Clin Lung Cancer 2025 Jun 10:S1525-7304(25)00129.
PMID: 40582919